Skip to main content
SpringerLink
Log in

Unified understanding of MS course is required for drug development

  • Comment
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

The treatment of multiple sclerosis (MS) has evolved remarkably over the past 25 years. This progress has been enabled by advances in research, drug development and active engagement of the scientific community with regulatory authorities. However, an inconsistent approach to MS disease courses could have a negative impact on the drug development process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. [No authors listed.] FDA approves new drug to treat multiple sclerosis. US Food and Drug Administration https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm549325.htm (2017).

  2. [No authors listed.] New medicine for multiple sclerosis. European Medicines Agency http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/11/news_detail_002847.jsp&mid=WC0b01ac058004d5c1 (2017).

  3. Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278–286 (2014).

    Article  Google Scholar 

  4. Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis (European Medicines Agency, 2015).

  5. U.S. Food and Drug Administration. Ocrelizumab Summary Review. US Food and Drug Administration https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053Orig1s000SumR.pdf (2017).

Download references

Acknowledgements

A.J.T. acknowledges support from the UCL/UCLH National Institute of Health (NIHR) Biomedical Research Centre (BRC).

Author information

Authors and Affiliations

  1. National Multiple Sclerosis Society, 733 Third Avenue, New York, 10017, New York, USA

    Timothy Coetzee

  2. Faculty of Brain Sciences, University College London, 149 Tottenham Court Road, London, W1T 7NF, UK

    Alan J. Thompson

Authors
  1. Timothy Coetzee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan J. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan J. Thompson.

Ethics declarations

Competing interests

A.J.T. is chair and T.C. a member of the International Progressive MS Alliance Scientific Steering Committee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coetzee, T., Thompson, A. Unified understanding of MS course is required for drug development. Nat Rev Neurol 14, 191–192 (2018). https://doi.org/10.1038/nrneurol.2017.184

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2017.184

  • Springer Nature Limited

This article is cited by

Search

Navigation